BACKGROUND:Bone mineral density declines by 2-6% within 1-2 years after initiation of antiretroviral therapy (ART); however, it is uncertain whether this results in an immediate or cumulative increase in fracture rates. METHODS: We evaluated the incidence and predictors of fracture in 4640 HIV-positive participants from 26 randomized ART studies followed in the AIDS Clinical Trials Group (ACTG) Longitudinal-Linked Randomized Trial study for a median of 5 years. Fragility and nonfragility fractures were recorded prospectively at semiannual visits. Incidence was calculated as fractures/total person-years. Cox proportional hazards models evaluated effects of traditional fracture risks, HIV disease characteristics, and ART exposure on fracture incidence. RESULTS:Median (interquartile range) age was 39 (33, 45) years; 83% were men, 48% white, andmedian nadir CD4 cell count was 187 (65, 308) cells/μl. Overall, 116 fractures were reported in 106 participants with median time-to-first fracture of 2.3 years. Fracture incidence was 0.40 of 100 person-years among all participants and 0.38 of 100 person-years among 3398 participants who were ART naive at enrollment into ACTG parent studies. Among ART-naive participants, fracture rates were higher within the first 2 years after ART initiation (0.53/100 person-years) than subsequent years (0.30/100 person-years). In a multivariate analysis of ART-naive participants, increased hazard of fracture was associated with current smoking and glucocorticoid use but not with exposure to specific antiretrovirals. CONCLUSION:Fracture rates were higher within the first 2 years after ART initiation, relative to subsequent years. However, continuation of ART was not associated with increasing fracture rates in these relatively young HIV-positive individuals.
RCT Entities:
BACKGROUND: Bone mineral density declines by 2-6% within 1-2 years after initiation of antiretroviral therapy (ART); however, it is uncertain whether this results in an immediate or cumulative increase in fracture rates. METHODS: We evaluated the incidence and predictors of fracture in 4640 HIV-positive participants from 26 randomized ART studies followed in the AIDS Clinical Trials Group (ACTG) Longitudinal-Linked Randomized Trial study for a median of 5 years. Fragility and nonfragility fractures were recorded prospectively at semiannual visits. Incidence was calculated as fractures/total person-years. Cox proportional hazards models evaluated effects of traditional fracture risks, HIV disease characteristics, and ART exposure on fracture incidence. RESULTS: Median (interquartile range) age was 39 (33, 45) years; 83% were men, 48% white, and median nadir CD4 cell count was 187 (65, 308) cells/μl. Overall, 116 fractures were reported in 106 participants with median time-to-first fracture of 2.3 years. Fracture incidence was 0.40 of 100 person-years among all participants and 0.38 of 100 person-years among 3398 participants who were ART naive at enrollment into ACTG parent studies. Among ART-naive participants, fracture rates were higher within the first 2 years after ART initiation (0.53/100 person-years) than subsequent years (0.30/100 person-years). In a multivariate analysis of ART-naive participants, increased hazard of fracture was associated with current smoking and glucocorticoid use but not with exposure to specific antiretrovirals. CONCLUSION:Fracture rates were higher within the first 2 years after ART initiation, relative to subsequent years. However, continuation of ART was not associated with increasing fracture rates in these relatively young HIV-positive individuals.
Authors: Ronald J Bosch; Kara Bennett; Ann C Collier; Robert Zackin; Constance A Benson Journal: J Acquir Immune Defic Syndr Date: 2007-03-01 Impact factor: 3.731
Authors: P Rivas; M Górgolas; R García-Delgado; M Díaz-Curiel; A Goyenechea; M L Fernández-Guerrero Journal: HIV Med Date: 2007-12-18 Impact factor: 3.180
Authors: Isabel Cassetti; José Valdez R Madruga; Jamal Muhamad A H Suleiman; Arnaldo Etzel; Lijie Zhong; Andrew K Cheng; Jeffrey Enejosa Journal: HIV Clin Trials Date: 2007 May-Jun
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Michael P Dube; Richard Haubrich; Jeannie Huang; Sharon Riddler; Pablo Tebas; Andrew R Zolopa; Ann C Collier; Todd T Brown Journal: Clin Infect Dis Date: 2013-08-13 Impact factor: 9.079
Authors: E Mutimura; Q Shi; D R Hoover; K Anastos; E Rudakemwa; J C Dusingize; J D Sinabye; M T Yin Journal: HIV Med Date: 2016-11 Impact factor: 3.180
Authors: Michelle A Kendall; Katherine Tassiopoulos; Grace A McComsey; Michael T Yin Journal: AIDS Res Hum Retroviruses Date: 2015-07-16 Impact factor: 2.205
Authors: Anjali Sharma; Qiuhu Shi; Donald R Hoover; Kathryn Anastos; Phyllis C Tien; Mary A Young; Mardge H Cohen; Elizabeth T Golub; Deborah Gustafson; Michael T Yin Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731